Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims‑based retrospective cohort study.

Autor:	To TM; Genentech Inc, South San Francisco, CA, USA., Ta JT; Genentech Inc, South San Francisco, CA, USA., Patel AM; Genentech Inc, South San Francisco, CA, USA., Arndorfer S; Genesis Research, Hoboken, NJ, USA., Abbass IM; Genentech Inc, South San Francisco, CA, USA., Gandhy R; Genentech Inc, South San Francisco, CA, USA.
Jazyk:	angličtina
Zdroj:	Journal of medical economics [J Med Econ] 2023 Jan-Dec; Vol. 26 (1), pp. 862-870.
DOI:	10.1080/13696998.2023.2228166
Abstrakt:	Aims: Quantify healthcare resource utilization (HRU) and costs for individuals with late-onset Huntington's disease (LoHD) and compare these with adult-onset HD (AoHD) and non-HD controls. Methods: This retrospective cohort study used US healthcare claims data from the IBM MarketScan Commercial and Medicare Supplemental Databases. Individuals newly diagnosed with HD between 1/1/2009 and 12/31/2017 were selected (index date was first HD claim). Individuals ≥60 years of age at the index date were categorized as having LoHD while individuals 21-59 years of age were categorized as having AoHD. Non‑HD controls were exact matched 2:1 to LoHD and AoHD cohorts. Individuals were required to have continuous enrollment for ≥12 months pre- and post-index. Twelve-month all-cause HRU and healthcare costs were assessed for each cohort. Results: In total, 763 individuals with LoHD and 1,073 individuals with AoHD were matched with 3,762 non-HD controls. Unadjusted all-cause HRU in the 12 months post-index was higher for individuals with LoHD and AoHD compared with non-HD controls across most service categories. Adjusted all-cause HRU for the LoHD cohort was significantly higher compared with non-HD controls across all service categories. In the 12 months post-index, mean total costs for the LoHD cohort ($29,055) were significantly higher than for non-HD controls (≥60 years old: $17,286; 21-59 years old: $12,688; p <.001) and similar to total costs in the AoHD cohort ($31,701; p =.47). Limitations: It was not possible to control for differences in HD stage but regression models were adjusted for baseline HRU. Evaluations of costs did not include indirect costs, which are known to be significant components of the wider HD burden. Conclusions: This study provides the first analysis of HRU and costs in LoHD, demonstrating that individuals with LoHD experience a significantly higher healthcare burden compared with non-HD controls and a similarly high burden compared with individuals with AoHD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu